Tyrosine kinase inhibitors (TKIs) such as imatinib, sunitinib and regorafenib serve as the first, second, and third line treatment, respectively, by targeting KIT and PDGFRA. Additionally, avapritinib is specifically utilized for GIST cases harboring PDGFRA exon 18 mutations. Here, KIT is linked to gastrointestinal stromal tumor.